Overview
Syllabus
Intro
Changing Geographic Distribution of IBD
Main Susceptibility Genes for Crohn's Disease
Microbial Diversity in Crohn's Disease
Management of Mild to Moderate UC
Estimate of Efficacy of AZA for Treatment Success in UC Patients: Meta-Analysis
Infliximab for UC: ACT 1 and ACT 2 Clinical Remission
ACT1/2 Trials: Survival Free of Colectomy
Cyclosporine vs. Infliximab for Acute Severe UC Treatment Failure, %
Management of Crohn's Disease
Construct of Biologic Agents Used in Crohn's Disease
Induction of Clinical Remission at Week 4 In Crohn's Disease: Certolizumab, Adalimumab, Infliximab
Natalizumab (Anti-Alpha 4 Integrin) Therapy for Crohn's Disease
Baseline Factors Associated with Time to Surgery: Crohn's, Olmsted County, 1970-2004
Advances in IBD Natural History: Predictors of More Severe Disease
CT Enterography Healing: Equivalent to Mucosal Healing at Endoscopy?
TPMT Activity in 407 New Zealand Patients
Meta-Analysis: Association Between 6-TGN Levels and Clinical Remission
Effect of Trough Serum Infliximab Concentrations on Clinical Outcome at 52 Weeks
What Factors influence the Pharmacokinetics of TNF Antagonists?
Active Monitoring of Anti-TNF Levels May Ensure Durability of Response
Effect of Concomitant Azathioprine or Methotrexate on Anti-drug Antibodies
Taught by
Mary Greeley Medical Center